Goldman Sachs’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$3.74M Sell
215,999
-91,710
-30% -$1.59M ﹤0.01% 3012
2025
Q1
$6.73M Buy
307,709
+64,742
+27% +$1.42M ﹤0.01% 2521
2024
Q4
$7.75M Buy
242,967
+47,901
+25% +$1.53M ﹤0.01% 2522
2024
Q3
$5.63M Buy
195,066
+48,140
+33% +$1.39M ﹤0.01% 2672
2024
Q2
$5.64M Sell
146,926
-172,550
-54% -$6.62M ﹤0.01% 2525
2024
Q1
$18.8M Buy
319,476
+8,893
+3% +$523K ﹤0.01% 1594
2023
Q4
$18.6M Sell
310,583
-21,210
-6% -$1.27M ﹤0.01% 1625
2023
Q3
$12.6M Sell
331,793
-303,104
-48% -$11.5M ﹤0.01% 1823
2023
Q2
$57.8M Sell
634,897
-28,298
-4% -$2.58M 0.01% 854
2023
Q1
$43.7M Sell
663,195
-398,508
-38% -$26.3M 0.01% 995
2022
Q4
$54.9M Buy
1,061,703
+104,025
+11% +$5.38M 0.01% 919
2022
Q3
$65.4M Buy
957,678
+147,279
+18% +$10.1M 0.02% 809
2022
Q2
$36.6M Buy
810,399
+310,145
+62% +$14M 0.01% 1169
2022
Q1
$25.4M Buy
500,254
+2,172
+0.4% +$110K 0.01% 1550
2021
Q4
$23.5M Sell
498,082
-525,088
-51% -$24.8M ﹤0.01% 1643
2021
Q3
$33.7M Buy
1,023,170
+329,130
+47% +$10.8M 0.01% 1349
2021
Q2
$43.9M Sell
694,040
-429,701
-38% -$27.2M 0.01% 1174
2021
Q1
$48.2M Buy
1,123,741
+34,210
+3% +$1.47M 0.01% 1053
2020
Q4
$62.3M Sell
1,089,531
-242,079
-18% -$13.8M 0.02% 816
2020
Q3
$40.2M Buy
1,331,610
+318,550
+31% +$9.61M 0.01% 997
2020
Q2
$33.1M Buy
1,013,060
+378,343
+60% +$12.4M 0.01% 1139
2020
Q1
$17M Buy
634,717
+168,482
+36% +$4.51M 0.01% 1434
2019
Q4
$14.3M Buy
466,235
+101,602
+28% +$3.11M ﹤0.01% 1833
2019
Q3
$8.78M Sell
364,633
-56,223
-13% -$1.35M ﹤0.01% 2004
2019
Q2
$10.7M Buy
420,856
+223,238
+113% +$5.66M ﹤0.01% 1920
2019
Q1
$3.85M Buy
197,618
+139,510
+240% +$2.72M ﹤0.01% 2597
2018
Q4
$767K Sell
58,108
-14,892
-20% -$197K ﹤0.01% 3249
2018
Q3
$1.3M Buy
73,000
+8,330
+13% +$148K ﹤0.01% 3074
2018
Q2
$1.42M Buy
+64,670
New +$1.42M ﹤0.01% 3032